Considering immuno-autonomics in stratifying successful treatment of rheumatoid arthritis with tumor necrosis factor inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19 by Holman, AJ, Keystone, E, Choy, E, Taylor, P, Gaylis, N

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis by Weinblatt, M, Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, de Bono, S, Tanaka, Y

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis by Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, de Bono, S, Rooney, T, Tanaka, Y

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis by Tanaka, Y, Fautrel, B, Keystone, E, Ortmann, R, Zhu, B, Issa, M, Patel, H, De Bono, S, Rooney, T, Taylor, P

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis by Kremer, J, Genovese, M, Keystone, E, Taylor, P, Zuckerman, S, Ruotolo, G, Schlichting, D, Crotzer, V, Nantz, E, Beattie, S, Macias, W

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis by Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, De Bono, S, Rooney, T, Tanaka, Y, Faraawi, R

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirhe... by Genovese, M, Keystone, E, Taylor, P, Drescher, E, Berclaz, P, Lee, C, Schlichting, D, Beattie, S, Fidelus-Gort, R, Luchi, M, Macias, W

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS by Taylor, P, Genovese, M, Keystone, E, Drescher, E, Berclaz, P, Lee, C, Fidelus-Gort, R, Schlichting, D, Beattie, S, Luchi, M, Macias, W

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. by Keystone, E, Taylor, P, Drescher, E, Schlichting, D, Beattie, S, Berclaz, P, Lee, C, Fidelus-Gort, R, Luchi, M, Rooney, T, Macias, W, Genovese, M

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modify... by Peterfy, C, Emery, P, Genovese, M, Keystone, E, Taylor, P, Berclaz, P, DiCarlo, J, Lee, C, Schlichting, D, Beattie, S, Luchi, M, Macias, W

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study by Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study by Keystone, E, Taylor, P, Tanaka, Y, Gaich, C, DeLozier, A, Dudek, A, Zamora, J, Covarrubias Cobos, J, Rooney, T, de Bono, S, Arora, V, Linetzky, B, Weinblatt, M

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’... by Taylor, P, Keystone, E, Van Der Heijde, D, Tanaka, Y, Ishii, T, Emoto, K, Yang, L, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, De Bono, S, Weinblatt, M, Combe, B

Baricitinib versus placebo or adalimumab in rheumatoid arthritis by Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). by Furst, D, Breedveld, F, Burmester, G, Crofford, J, Emery, P, Feldmann, M, Kalden, JR, Kavanaugh, A, Keystone, E, Klareskog, L, Lipsky, P, Maini, R, Russell, A, Scott, D, Smolen, J, Van de Putte, L, Visher, T, Weisman, M

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summar... by Taylor, P, Krogulec, M, Dudek, A, Dudler, J, Drescher, E, Cseuz, R, Kausiene, R, Andersone, D, Unikiene, D, Sanchez Burson, J, Blanco Alonso, R, Dvorak, Z, Ghizdavescu, A, Irto, I, Larsson, E, Bello, N, Barry, J, Durand, F, Holzkaemper, T, Otawa, S, De Bono, S, Keystone, E, Rubbert-Roth, A, Combe, B, De La Torre, I